Vyome vs Soligenix
HIND and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and SNGX compare
Vyome is the larger company, worth 1.8 times as much as Soligenix ($10.8M against $6.1M).
Soligenix scores higher on the StockData Score (6 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $10.8M | $6.1M |
| Share price | $1.54 | $0.281 |
| Change, 1 year | −68.3% | −79.5% |
| Change, 5 years | −100.0% | −99.9% |
| Beta (5Y) | 1.60 | 2.38 |
| Employees | 18 | 14 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 83.6× | – |
| P/B | – | 0.9× |
| Growth | ||
| Revenue growth (TTM) | −67.1% | – |
| Revenue growth, 5Y average | −51.0% | – |
| Profitability | ||
| Gross margin | 52.7% | – |
| Operating margin | −9190% | – |
| Net margin | −8717% | – |
| Return on equity | −194% (better) | −242% |
| Return on invested capital | −173% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −285.8× | – |
| Current ratio | 4.37 (better) | 2.77 |
| Altman Z-score | −13.57 (better) | −35.09 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 39.6% | – |
| Shareholder yield | 39.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 2.0% | 4.3% |
| Held by insiders | 6.8% | 0.69% |
| Short interest, % of float | 0.28% | 0.31% |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.